• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The therapeutic potential of GLP-1 receptor antagonists for the treatment of spinal cord injury

Research Project

Project/Area Number 18K09084
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56020:Orthopedics-related
Research InstitutionTokai University

Principal Investigator

KATOH Hiroyuki  東海大学, 医学部, 講師 (40348678)

Co-Investigator(Kenkyū-buntansha) 渡辺 雅彦  東海大学, 医学部, 教授 (40220925)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords脊髄損傷 / 小胞体ストレス / グルカゴン用ペプチド-1受容体作動薬 / エキセナチド / マクロファージ極性 / GLP-1受容体作動薬 / オリゴデンドロサイト前駆細胞 / オリゴデンドロサイト / アポトーシス / マクロファージ / オリゴデンドロサイト前駆細胞(OPC)
Outline of Final Research Achievements

The effects of administering the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide after spinal cord injury (SCI) were examined in a rat contusion model. Compared to control animals that received PBS administration, the animals that received exenatide administration immediately after and 7 days after SCI had a significantly higher endoplasmic reticulum stress response levels along with a shift in the polarization of infiltrating macrophages leading to higher levels of anti-inflammatory M2 macrophages. The animals that received exenatide treatment did not suffer from hypoglycemia and showed significantly higher hindlimb motor function, demonstrating the therapeutic effects of exenatide for SCI.

Academic Significance and Societal Importance of the Research Achievements

脊髄損傷後の再生医療では幹細胞移植が注目されているが,二次障害を軽減する薬物療法の確立はより多くの患者を救助する可能性が高いと考えられ,GLP-1受容体作動薬エキセナチド投与により脊髄損傷後の機能障害が軽減できることを確認した意義は大きい.エキセナチドは糖尿病治療薬として臨床応用されているため安全性に問題はなく,さらに糖尿病ではなくても低血糖などの副作用が発生しないことを確認した.今後その治療メカニズムをさらに解明する必要があるが,早期臨床応用に向けた確実な第一歩を踏み出せた.

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (6 results)

All 2020 2019 2018

All Presentation (6 results) (of which Int'l Joint Research: 2 results)

  • [Presentation] 脊髄損傷に対するGLP-1受容体作動薬の作用2020

    • Author(s)
      野口俊洋,加藤裕幸,山口慶子,野村慧,渡辺雅彦
    • Organizer
      第35回 日本整形外科学会基礎学術集会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 脊髄損傷ラットにおけるGLP-1受容体作動薬のマクロファージ極性と血液脳脊髄関門への作用の検討2020

    • Author(s)
      山口慶子,加藤裕幸,野口俊洋,渡辺雅彦
    • Organizer
      第39回 日本運動器・移植再生医学研究会
    • Related Report
      2020 Annual Research Report
  • [Presentation] The effects of GLP-1 receptor agonist administration for the treatment of spinal cord injury in a rat model2020

    • Author(s)
      Toshihiro Noguchi, Hiroyuki Katoh, Keiko Yamaguchi, Satoshi Nomura, Masahiko Watanabe
    • Organizer
      Orthopaedic Research Society 2020 Annual Meeting
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research
  • [Presentation] 脊髄損傷に対するGLP-1受容体作動薬の作用 ー マクロファージの極性に関する免疫組織学的検討 ー2019

    • Author(s)
      野口俊洋,加藤裕幸,山口慶子,野村慧,渡辺雅彦
    • Organizer
      第34回 日本整形外科学会基礎学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] GLP-1 receptor agonist enhances the ER stress response and improves functional recovery after spinal cord injury in a rat model2019

    • Author(s)
      Satoshi Nomura, Hiroyuki Katoh, Sho Yanagisawa, Takeshi Imai, Masahiro Kuroiwa, Masahiko Watanabe
    • Organizer
      Orthopaedic Research Society 2018 Annual Meeting
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] 脊髄損傷に対するGLP-1受容体作動薬の作用 ー 小胞体ストレス応答能の増強 ー2018

    • Author(s)
      野村慧,加藤裕幸,野口俊洋,柳澤聖,今井洸,渡辺雅彦
    • Organizer
      第33回 日本整形外科学会基礎学術集会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi